[Guidelines for the evaluation and management of chronic heart failure].
The Japanese Circulation Society have long been involved in the development of practice guidelines designed to assist physicians in the management of chronic heart failure. Importantly, as our population ages, the incidence of chronic heart failure and its mortality rate will continue to increase. Furthermore, recent advances in our understanding of the pathophysiology of chronic heart failure and new developments in the therapy of this disorder have greatly expanded the information base which to make decisions. The guidelines for the evaluation and management of chronic heart failure were developed by cardiovascular specialists and were based primarily on a comprehensive review of published reports. Furthermore, these guidelines are based on the assumption that the resources necessary to provide this care readily available.
Ohkusa
Tomoko
T
Department of Cardiovascular Medicine, Division of Medical Bioregulation, Yamaguchi University School of Medicine.
Matsuzaki
Masunori
M
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001243:Assisted Circulation; D002908:Chronic Disease; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000175:diagnosis / Q000628:therapy*; D016027:Heart Transplantation; D006801:Humans; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004071:Digitalis Glycosides; D004232:Diuretics; D000638:Amiodarone